Current therapies and targets for type 2 diabetes mellitus

被引:54
作者
Chellappan, Dinesh K. [1 ]
Yap, Wei S. [2 ]
Ahmad Suhaimi, Nurfatihah A. B. T. [2 ]
Gupta, Gaurav [3 ]
Dua, Kamal [4 ]
机构
[1] Int Med Univ, Dept Life Sci, Kuala Lumpur, Malaysia
[2] Int Med Univ, Sch Hlth Sci, Kuala Lumpur, Malaysia
[3] Jaipur Natl Univ, Sch Pharmaceut Sci, Jaipur, Rajasthan, India
[4] Sydney Univ Technol, Grad Sch Hlth, Dept Pharm, Ultimo, Australia
关键词
Diabetes mellitus; type; 2; Therapeutics; Review; PROTEIN-COUPLED RECEPTOR; CHAIN FATTY-ACIDS; CENTRAL-NERVOUS-SYSTEM; BETA-CELL FUNCTION; ADD-ON THERAPY; INSULIN-SECRETION; GLUCOSE-TOLERANCE; GENE-EXPRESSION; GLUCOKINASE ACTIVATORS; ENTEROENDOCRINE CELLS;
D O I
10.23736/S0031-0808.18.03455-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prevalence of type 2 diabetes mellitus (T2DM) has been increasing at an alarming rate. With an increased understanding of the pathophysiology and pathogenesis of T2DM, various new therapeutic options have been developed to target different key defects in T2DM. Incremental innovations of existing therapies either through unprecedented drug combinations, modified drug molecules, or improved delivery systems are capable to nullify some of the undesirable side effects of traditional therapies as well as to enhance effectiveness. The existing administration routes include inhalation, nasal, buccal, parenteral and oral. Newer drug targets such as protein kinase B (Akt/PKB), AMP-activated protein kinase (AMPK), sirtuin (SIRT), and others are novel approaches that act via different mechanisms and possibly treating T2DM of distinct variations and aetiologies. Other therapies such as endobarrier, gene therapy, and stem cell technology utilize advanced techniques to treat T2DM, and the potential of these therapies are still being explored. Gene therapy is plausible to fix the underlying pathology of T2DM instead of using traditional reactive treatments, especially with the debut of Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein9 (CRISPR-Cas9) gene editing tool. Molecular targets in T2DM are also being extensively studied as it could target the defects at the molecular level. Furthermore, antibody therapies and vaccinations are also being developed against T2DM; but the ongoing clinical trials are relatively lesser and the developmental progress is slower. Although, there are many therapies designed to cure T2DM, each of them has their own advantages and disadvantages. The preference for the treatment plan usually depends on the health status of the patient and the treatment goal. Therefore, an ideal treatment should take patient's compliance, efficacy, potency, bioavailability, and other pharmacological and non-pharmacological properties into account.
引用
收藏
页码:117 / 131
页数:15
相关论文
共 146 条
[1]   Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes [J].
Ahren, Bo .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (05) :369-385
[2]   Diabetes Causes Bone Marrow Autonomic Neuropathy and Impairs Stem Cell Mobilization via Dysregulated p66Shc and Sirt1 [J].
Albiero, Mattia ;
Poncina, Nicol ;
Tjwa, Marc ;
Ciciliot, Stefano ;
Menegazzo, Lisa ;
Ceolotto, Giulio ;
de Kreutzenberg, Saula Vigili ;
Moura, Rute ;
Giorgio, Marco ;
Pelicci, Piergiuseppe ;
Avogaro, Angelo ;
Fadini, Gian Paolo .
DIABETES, 2014, 63 (04) :1353-1365
[3]   Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes [J].
Amin, N. B. ;
Aggarwal, N. ;
Pall, D. ;
Paragh, G. ;
Denney, W. S. ;
Le, V. ;
Riggs, M. ;
Calle, R. A. .
DIABETES OBESITY & METABOLISM, 2015, 17 (08) :751-759
[4]  
[Anonymous], 2015, Med Lett Drugs Ther, V57, P139
[5]  
[Anonymous], 2004, Drugs R D, V5, P98
[6]  
[Anonymous], MEDICINE BALTIMORE, DOI DOI 10.1097/MD.0000000000007201
[7]  
Baars Annemarie, 2015, Microorganisms, V3, P641, DOI 10.3390/microorganisms3040641
[8]   SirT1 Gain of Function Increases Energy Efficiency and Prevents Diabetes in Mice [J].
Banks, Alexander S. ;
Kon, Ning ;
Knight, Colette ;
Matsumoto, Michihiro ;
Gutierrez-Juarez, Roger ;
Rossetti, Luciano ;
Gu, Wei ;
Accili, Domenico .
CELL METABOLISM, 2008, 8 (04) :333-341
[9]   Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus [J].
Belle, Luziane Potrich ;
Rodrigues Bitencourt, Paula Eliete ;
De Bona, Karine Santos ;
Moresco, Rafael Noal ;
Moretto, Maria Beatriz .
CLINICA CHIMICA ACTA, 2012, 413 (11-12) :1020-1021
[10]   Calorie restriction, SIRT1 and metabolism: Understanding longevity [J].
Bordone, L ;
Guarente, L .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (04) :298-305